Updated on 8 April 2013
In markets where Daiichi Sankyo's is stronger, it takes the lead to promote both its own innovator products and Ranbaxy's generic products. This gives Ranbaxy a distinct edge as it is among the few global generic companies offering a wide range of both generic and innovator products.
As a part of hybrid business model, Ranbaxy inked a deal in June 2012 with Daiichi Sankyo Venezuela to expand its presence in Venezuela, which is the third biggest market in Latin America. Ranbaxy is planning to sell its products through Daiichi Sankyo Venezuela. The deal will increase the Ranbaxy presence and also further strengthen Daiichi's presence in the area.